A novel role of alkaline phosphatase in the ERK1/2 dephosphorylation in renal cell carcinoma cell lines: A new plausible therapeutic target

Biochimie

Volumn 107, Issue PB, 2014, Pages 406-409

  Sharma, Ujjawal ^a   Pal, Deeksha ^a   Prasad, Rajendra ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

ERK1 2; L B K alkaline phosphatase; Phosphorylation; Transfection

Indexed keywords

ALKALINE PHOSPHATASE; COMPLEMENTARY DNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MAPK1 PROTEIN, HUMAN;

ARTICLE; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; IN VITRO STUDY; KIDNEY CARCINOMA; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; HUMAN; KIDNEY TUMOR; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE;

ALKALINE PHOSPHATASE; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; DNA, COMPLEMENTARY; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; KIDNEY NEOPLASMS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MOLECULAR TARGETED THERAPY; PHOSPHORYLATION; TRANSFECTION;

EID: 84915771341     PISSN: 03009084     EISSN: 61831638     Source Type: Journal    
DOI: 10.1016/j.biochi.2014.09.016     Document Type: Article

References (34)

1. R. Siegel, J. Ma, Z. Zou, and A. Jemal Cancer Statistics, 2014 CA Cancer J. Clin. 64 2014 9 29
2. M. Itsumi, and K. Tatsugami Immunotherapy for renal cell carcinoma Clin. Dev. Immunol. 2010 2010 284581
3. V.L. Goodman, E.P. Rock, R. Dagher, R.P. Ramchandani, S. Abraham, J.V. Gobburu, B.P. Booth, S.L. Verbois, D.E. Morse, C.Y. Liang, N. Chidambaram, J.X. Jiang, S. Tang, K. Mahjoob, R. Justice, and R. Pazdur Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma Clin. Cancer Res. 13 2007 1367 1373
4. R.C. Kane, A.T. Farrell, H. Saber, S. Tang, G. Williams, J.M. Jee, C. Liang, B. Booth, N. Chidambaram, D. Morse, R. Sridhara, P. Garvey, R. Justice, and R. Pazdur Sorafenib for the treatment of advanced renal cell carcinoma Clin. Cancer Res. 12 2006 7271 7278
5. M. Buczek, B. Escudier, E. Bartnik, C. Szczylik, and A. Czarnecka Resistance to tyrosine kinase inhibitors in clear cell renal cell carcinoma: from the patients's bed to molecular mechanism Biochim. Biophys. Acta 1845 2014 31 41
6. I. Tamaskar, J. Dhillon, and R. Pili Resistance to angiogenesis inhibitors in renal cell carcinoma Clin. Adv. Hematol. Oncol. 9 2011 101 110
7. B. Casar, J. Rodríguez, G. Gibor, R. Seger, and P. Crespo Mxi2 sustains ERK1/2 phosphorylation in the nucleus by preventing ERK1/2 binding to phosphatases Biochem. J. 441 2012 571 578
8. R.J. Santen, R.X. Song, R. McPherson, R. Kumar, L. Adam, M.H. Jeng, and W. Yue The role of mitogen-activated protein (MAP) kinase in breast cancer J. Steroid Biochem. Mol. Biol. 80 2002 239 256
9. R.M. Uht, S. Amos, P.M. Martin, A.E. Riggan, and I.M. Hussaini The protein kinase C-eta isoform induces proliferation in glioblastoma cell lines through an ERK/Elk-1 pathway Oncogene 26 2007 2885 2893
10. Y. Chen, I. Nowak, J. Huang, P.C. Keng, H. Sun, H. Xu, G. Wei, and S.O. Lee Erk/MAP kinase signaling pathway and neuroendocrine differentiation of non-small-cell lung cancer J. Thorac. Oncol. 9 2014 50 58
11. B. Liang, S. Wang, X.G. Zhu, Y.X. Yu, Z.R. Cui, and Y.Z. Yu Increased expression of mitogen-activated protein kinase and its upstream regulating signal in human gastric cancer World J. Gastroenterol. 11 2005 623 628
12. P.J. Roberts, and C.J. Der Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer Oncogene 26 2007 3291 32310
13. H. Oka, Y. Chatani, R. Hoshino, O. Ogawa, Y. Kakehi, T. Terachi, Y. Okada, M. Kawaichi, M. Kohno, and O. Yoshida Constitutive activation of mitogen-activated protein (MAP) kinases in human renal cell carcinoma Cancer Res. 55 1995 4182 4187
14. L. Campbell, R. Nuttall, D. Griffiths, and M. Gumbleton Activated extracellular signal-regulated kinase is an independent prognostic factor in clinically confined renal cell carcinoma Cancer 115 2009 3457 3467
15. D. Huang, Y. Ding, W.M. Luo, S. Bender, C.N. Qian, E. Kort, Z.F. Zhang, K.V. Beldt, N.S. Duesbery, J.H. Resau, and B.T. Teh Inhibition of MAPK kinase signaling pathways suppressed renal cell carcinoma growth and angiogenesis in vivo Cancer Res. 68 2008 81 88
16. L. Campbell, G. Al-Jayyoussi, R. Gutteridge, N. Gumbleton, R. Griffiths, S. Gumbleton, M.W. Smith, D.F.R. Griffiths, and M. Gumbleton Caveolin-1 in renal cell carcinoma promotes tumour cell invasion, and in co-operation with pERK predicts metastases in patients with clinically confined disease J. Transl. Med. 11 2013 255
17. C.J. Caunt, and S.M. Keyse Dual-specificity MAP kinase phosphatases (MAPKs): shaping the outcome of MAP kinase signaling FEBS J. 280 2013 489 504
18. B. Zhou, Z.X. Wang, Y. Zhao, D.L. Brautigan, and Z.Y. Zhang The specificity of extracellular signal-regulated kinase 2 dephosphorylation by protein phosphatases J. Biol. Chem. 277 2002 31818 31825
19. U. Sharma, D. Pal, and R. Prasad Alkaline phosphatase: an overview Ind. J. Clin. Biochem. 29 2014 269 278
20. M.C. Manara, N. Baldini, M. Serra, P.L. Lollini, C. De Giovanni, M. Vaccari, A. Argnani, S. Benini, D. Maurici, P. Picci, and K. Scotlandi Reversal of malignant phenotype in human osteosarcoma cells transduced with the alkaline phosphatase gene Bone 26 2000 215 220
21. R. Prasad, S. Lambe, P. Kaler, S. Pathania, S. Kumar, S. Attari, and S.K. Singh Ectopic expression of alkaline phosphatase in proximal tubular brush border membrane of human renal cell carcinoma Biochim. Biophys. Acta 1741 2005 240 245
22. U. Sharma, S.K. Singh, D. Pal, R. Khajuria, A.K. Mandal, and R. Prasad Implication of BBM lipid composition and fluidity in mitigated alkaline phosphatase activity in renal cell carcinoma Mol. Cell. Biochem. 369 2012 287 293
23. U. Sharma, D. Pal, S.K. Singh, K. Nandita, and R. Prasad Reduced L/B/K alkaline phosphatase gene expression in renal cell carcinoma: plausible role in tumorigenesis Biochimie 104 2014 27 35
24. T method Nat. Protoc. 3 2008 1101 1108
25. O.H. Lowry, N.J. Roserbrough, A.L. Farr, and R.L. Randall Protein measurement with folin phenol reagent J. Biol. Chem. 193 1951 265 275
26. A. Alonso, J. Sasin, N. Bottini, I. Friedberg, I. Friedberg, A. Osterman, A. Godzik, T. Hunter, J. Dixon, and T. Mustelin Protein tyrosine phosphatases in the human genome Cell 117 2004 699 711
27. R. Roskoski Jr. ERK1/2 MAP kinases: structure, function, and regulation Pharmacol. Res. 66 2012 105 143
28. X. Deschenes-Simard, F. Kottakis, S. Meloche, and G. Ferbeyre ERKs in cancer: friends or foes? Cancer Res. 74 2014 412 419
29. C. Montagut, and J. Settleman Targeting the RAF-MEK-ERK pathway in cancer therapy Cancer Lett. 283 2009 125 134
30. L. Adnane, P.A. Trail, I. Taylor, and S.M. Wilhelm Sorafenib (BAY 43-9006, Nexavar), a dual -action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature Methods Enzymol. 407 2006 597 612
31. B.B. Friday, and A.A. Adjei advances in targeting the Ras/Raf/MEK/ERK mitogen activated protein kinase cascade with MEK inhibitors for cancer therapy Clin. Cancer Res. 14 2008 342 346
32. Z. Fang, Y. Tang, J. Fang, Z. Zhou, Z. Xing, Z. Guo, X. Guo, W. Wang, W. Jiao, Z. Xu, and Z. Liu Simvastatin inhibits renal cancer cell growth and metastasis via AKT/mTOR, ERK and JAK2/STAT3 pathway PLoS One 8 2013 e62823
33. M.M. Goldenberg Pharmaceutical approval update P&T 39 2014 153 154
34. H. Gao, and L. Deng Sphingosine kinase-1 activation causes acquired resistance against sunitinib in renal cell carcinoma cells Cell. Biochem. Biophys. 68 2014 419 425